| Old Articles: <Older 7081-7090 Newer> |
|---|
 |
The Motley Fool
January 18, 2011
Brian Orelli |
Up 30%, Succeed Indeed! An aptly named clinical trial bodes well for Ariad Pharmaceuticals.   |
The Motley Fool
January 18, 2011
Russ Krull |
Keep It or Sweep It: Johnson & Johnson? Should the company be held or sold? |
The Motley Fool
January 18, 2011
Jim Royal |
How Do These Biotechs Really Make Their Money? Break it down using the Dupont formula. |
The Motley Fool
January 18, 2011
Jim Royal |
How Does Big Pharma Really Make Its Money? As investors, we need to understand how our companies truly make their money. Thankfully, there's a neat trick developed for just that purpose: the DuPont Formula. |
The Motley Fool
January 14, 2011
Brian Orelli |
Don't Have a Stroke Over Merck's Heart Drug Welcome to pharma investing. |
The Motley Fool
January 14, 2011
Seth Jayson |
Here's How Mindray Medical International May Be Failing You With recent TTM operating margins below historical averages, Mindray Medical International has some work to do, even though gross and net margins have held up reasonably well. |
Fast Company
February 2011
Elizabeth Svoboda |
How Samuel Stupp Is Rebuilding Your Body, One Molecule at a Time Making paralyzed mice walk was just the first step for Samuel Stupp. Now he and his team are on a mission to help our bodies repair themselves. |
Fast Company
February 2011 |
Designer Molecules The Stupp lab's bio-active nanofibers could help make regenerative medicine a reality. |
Chemistry World
January 13, 2011
Andrew Turley |
UK tilts towards appraisal of Avastin as eye drug The UK is moving closer to opening up the National Health Service to cancer drug Avastin (bevacizumab) for the treatment of eye conditions, such as age-related macular degeneration. |
The Motley Fool
January 13, 2011
Brian Orelli |
This Trendy Pharma Is Making a Stylish Move Merck signs up a CRO to help with biosimilars. |
| <Older 7081-7090 Newer> Return to current articles. |
